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Abstract
Silver nanoparticles (AgNP) are one of the most widely investigated metallic NPs due to their
promising antibacterial activities. In recent years, AgNP research has shifted beyond antimicrobial
use to potential applications in the medical arena. This shift coupled with the extensive commer-
cial applications of AgNP will further increase human exposure and the subsequent risk of
adverse effects that may result from repeated exposures and inefficient delivery, meaning
research into improved AgNP delivery is of paramount importance. In this study, AgNP were
encapsulated in a natural biosurfactant, dipalmitoylphosphatidylcholine, in an attempt to enhance
the intracellular delivery and simultaneously mediate the associated cytotoxicity of the AgNP. It
was noted that because of the encapsulation, liposomal AgNP (Lipo‐AgNP) at 0.625 μg ml–1
induced significant cell death in THP1 cell lines a notably lower dose than that of the uncoated
AgNP induced cytotoxicity. The induced cytotoxicity was shown to result in an increased level
of DNA fragmentation resulting in a cell cycle interruption at the S phase. It was shown that
the predominate form of cell death upon exposure to both uncoated AgNP and Lipo‐AgNP was
apoptosis. However, a reactive oxygen species‐independent activation of the executioner
caspases 3/7 occurred when exposed to the Lipo‐AgNP. These findings showed that encapsula-
tion of AgNP enhance AgNP cytotoxicity and mediates a reactive oxygen species‐independent
induction of apoptosis.
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1 | INTRODUCTION
Silver nanoparticles (AgNP) are one of the most crucial metals in
nanomedicine/nanotechnology. They have been investigated in the
treatment of bacterial diseases and are found to possess a striking anti-
microbial activity. AgNP are known to cause oxidative lesion that
destroys the bacterial cell wall, facilitating its entry into the cell to bind
to sulfhydryl groups of key proteins and bacterial DNA to disrupt crucial
metabolic processes and halt cell proliferation (Feng et al., 2000;
Grigor'eva et al., 2013; Wigginton et al., 2010). This has also led to the
worldwide commercialization of AgNP in an array of formats with up
to 24% of nanotechnology driven everyday consumer products world-
wide containing AgNP (Vance et al., 2015). Some of the AgNP‐based
consumable products include but are not limited to food packaging,
antibacterial creams, coatings in antimicrobial textiles and domestic
cleaning products. AgNP are widely used in medicine for dressing
wounds, in making orthodontic materials, coating of bone prosthesis,
coating of stents or catheters, cleaning surgical equipment and in cer-
tain contraceptive devices (Blaske et al., 2013; Correa et al., 2015;
Knetsch & Koole, 2011; Samuel & Guggenbichler, 2004). In recent
years, research involving AgNP has moved beyond investigating its
antibacterial properties. The possibility of AgNP as an anticancer drug
has been the subject of research due to the emergence of drug‐resistant
cancer cells and the discovery that AgNP possess an inherent cytotoxic
effect on cancer cells (Zhang, Liu, Shen, & Gurunathan, 2016).
With increasing applications of AgNP in consumable products and
in medicine there is an increased risk of exposure to the toxic side
effects of AgNP that may have leached into the environment. Benn
and Westerhoff (2008) showed that a sock coated with about
1.36 mg of AgNP can release 48% of its coating into water by simply
Received: 8 July 2017 Revised: 9 October 2017 Accepted: 19 October 2017
DOI: 10.1002/jat.3566
J Appl Toxicol. 2017;1–12. Copyright © 2017 John Wiley & Sons, Ltd.wileyonlinelibrary.com/journal/jat 1
shaking the sock in water or as much as 100% in four consecutive
washes. AgNP can also be released in the same manner from sham-
poos, toothpaste, detergents and medical apparels (Benn, Cavanagh,
Hristovski, Posner, & Westerhoff, 2010). It has been reported that
AgNP route of entry could be through oral, pulmonary or dermal
routes. Irrespective of the entry route, AgNP induced cell death
through the generation of reactive oxygen species (ROS), increased
DNA damage and impairment of mitochondrial functions (Kang, Jung,
& Lim, 2012). As such, continuous use of AgNP at these high concen-
trations comes with a potential danger in the near future. For instance,
inefficient delivery of AgNP to target cells could result in systemic tox-
icity as it has been previously reported that prolonged biodistribution
of AgNP could result in systemic transport to different tissues particu-
larly to the spleen and liver (Xue et al., 2012). As such, devising ways by
which low concentrations of AgNP can be efficiently delivered to tar-
get cells thus becomes pertinent. Generally, the unspecific systemic
activities of conventional anticancer drugs are the major limiting factor
in their application as chemotherapeutics. To subvert this negative side
effect, encapsulation of drugs in a lipid bilayer has been investigated
for improved delivery with promising results (Sercombe et al., 2015).
For example, doxorubicin is a potent anticancer drug that inhibits topo-
isomerase II preventing accessibility of DNA polymerase to the DNA.
Regardless of its potency, there is limitation to the use of doxorubicin
in cancer treatment due to the negative side effects following its
administration such as alopecia, hepatotoxicity, cardiotoxicity and
nephrotoxicity (Tacar, Sriamornsak, & Dass, 2013). However, liposomal
encapsulation of doxorubicin has been shown to improve its delivery in
addition to alleviating the negative side effects of the drug, reducing
the required concentration to achieve cell death (Brown & Khan,
2012; Camacho et al., 2016; Souto et al., 2016).
Liposomes like many other NPs have unique characteristics that
make them efficient drug delivery vehicles. They are suitable for
transporting both hydrophobic and hydrophilic molecules; the lipid
layer of liposomes can entrap hydrophobic drugs due to hydrophobic
interactions between the fatty acid chains and the drug while the
aqueous core of the liposome can also hold hydrophilic drugs (Bozzuto
& Molinari, 2015). In general, liposomes are often prepared from phos-
pholipids, which then form the outer layer of the nanostructure that
can be similar to the lipid bilayer of the cell membrane. The lipid layer
of liposomes aids the passive transport of the liposome and its associ-
ated content into the cell. This prevents the requirement of membrane
channels or pumps normally controlling the entry of charged or polar
molecules such as peptides, metals and synthetic compounds that
can be encapsulated in the lipid vesicle. These attributes allow for dose
intensification of compounds that are encapsulated within the lipo-
some while limiting any negative side effects associated with excess
free drug present in a non‐liposome delivery method (Silverman, Reyn-
olds, & Deitcher, 2013). Liposomes have controllable sizes and their
surface properties are easily modified in the synthesis process and
can be tailored to any functional delivery requirements. These proper-
ties coupled with an enhanced permeability and retention effect
in vivo, increases their ability to accumulate in a tumour microenviron-
ment, which is typically composed of leaky vessels and abnormal cell
junctions (Nehoff, Parayath, Domanovitch, Taurin, & Greish, 2014;
Xing, Hwang, & Lu, 2016).
In this study, AgNP were encapsulated in a liposome made of nat-
ural biosurfactant, dipalmitoyl phosphatidylcholine (DPPC) to improve
delivery due to increased permeabilization into the target cells. It is
hoped that such a system will not only reduce the non‐specific cyto-
toxic effect observed during AgNP treatment, but it may also reduce
the concentration of AgNP required to elicit the expected cytotoxic
response. Subsequently, this may help reduce the development of
resistant strains to AgNP‐based drug as well as eliminate the release
of AgNP in large quantities into the ecosystem.
2 | MATERIALS AND METHODS
2.1 | Materials and reagents
Silver nitrate (AgNO3) (CAS no.: 7761‐88‐8), sodium borohydride
(NaBH4) (CAS no.: 16940‐66‐2), DPPC (CAS no.: 63‐89‐8), cholesterol
(CAS no.: 57‐88‐5), propidium iodide (PI) (CAS no.: 25535‐16‐4) and
sodium azide (NAN3) (CAS no.: 26628‐22‐8) were all purchased from
Sigma‐Aldrich, Dublin, Ireland. All tissue culture plastics, 96‐well plates,
T75 and T25 flasks were purchased from Thermo Fisher Scientific,
Dublin, Ireland. Alamar blue (catalogue no. DAL1025), 6‐carboxy‐2′,7′‐
dichlorofluorescein diacetate (carboxy‐DCFDA dye; catalogue no.
C400) and CellEvent Caspase‐3/7 Green Detection Reagent and SYTOX
AADvanced Dead Cell Stain (catalogue no. C10740) Calcein‐AM dye
(lot no. 1475337) were all purchased from Life Technologies, through
Biosciences Ltd., Dublin, Ireland.
2.2 | Silver nanoparticle synthesis
AgNPs were produced by a borohydride reduction of silver nitrate as
detailed in Equation 1 below,
AgNO3 aqð Þ þNaBH4 aqð Þ ➔ Ag0 sð Þ þ ½ B2H6 gð Þ þ ½ H2 gð Þ þNaNO3 aqð Þ
(1)
Briefly, a 1 mM solution of AgNO3 and 2 mM solution of NaBH4
were prepared in ultrapure grade distilled water. To prevent agglomer-
ation of theAgNPduring the reduction process, the reactionwas carried
out at low temperature; 30 ml of NaBH4 was added to an Erlenmeyer
flask placed in an ice bath and stirred at 350 rpm for 30minutes to equil-
ibrate. At a drop per second rate, 6 ml of AgNO3 was added to the
NaBH4 solution under constant stirring. After all the AgNO3 had been
added, the stirring was stopped and the flask taken out of the ice bath.
To prevent further agglomeration of the AgNP the solution was placed
back on the stirrer and stirred until room temperaturewas achieved. The
resulting golden yellow solution was stable at 4°C.
2.3 | X‐ray diffraction and energy dispersive X‐ray
analysis of silver nanoparticle
Powdered X‐ray diffraction (XRD) characterization of AgNP was con-
ducted with a Philips diffractometer (Philips Inc., Westborough, USA)
using a monochromatic Cu‐Kα1 radiation source (λ = 1.5406 Å) oper-
ated at 40 keV, 30 mA and a 2θ angle pattern. The scanning was car-
ried out in the 20° to 80° region and the crystalline structure was
analysed by comparing the obtained result with that of the Joint
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Committee on Powder Diffraction Standards library. Energy dispersive
X‐ray of AgNP was carried out by drop casting 100 μl of AgNP on a sil-
icon (Si) wafer and analysed using a Hitachi SU‐70 (Hitachi, Tokyo,
Japan) Oxford Instruments 50 mm2 X‐Max silicon drift EDS detector
operated at 20 keV.
2.4 | Liposome preparation and encapsulation of
silver nanoparticle
Liposomes were prepared with a combination of DPPC and cholesterol
via modification of a dehydration–rehydration technique originally
reported byMugabe, Azghani, andOmri (2006). Initially, DPPC and cho-
lesterol were dissolved in 5 ml chloroform and the solution was mixed
until clear. It was then dried in a vacuum oven at 52°C overnight (above
melting temperature of DPPC). The resultant lipid cake was rehydrated
in distilled deionized water (ddH2O) at 60°C in a shaker. After the lipid
was rehydrated, an AgNP solution was added to make a final lipid con-
centration of 1mgml–1 of DPPC and 0.23mgml–1 of cholesterol to give
a 7:3 molar ratio (Briuglia, Rotella, McFarlane, & Lamprou, 2015). The
solution was then placed in the shaker at 60°C for another 20 minutes
after which it was vortexed and extruded through a 100 nm Nanosizer
polycarbonate extruder (TTScientific, Knoxville, USA). The resulting col-
loidal mixture was stored at 4°C before use.
2.5 | Estimating encapsulation efficiency of the
liposome
To estimate the encapsulation efficiency, Lipo‐AgNP were centrifuged
at 30 000 g for 1 hour and the supernatant harvested. The supernatant
was then analysed by atomic absorption spectrophotometry to esti-
mate the concentration of silver in the solution. The encapsulation effi-
ciency (E) of the liposome was then calculated using the formula below:
E ¼ Total AgNP added to liposome−AgNP in supernatant
Total AgNP added to liposome
×100 (2)
2.6 | Scanning and scanning transmission electron
micrograph analysis
Scanning electron micrograph (SEM) micrographs were obtained for all
AgNP and liposomal AgNP (Lipo‐AgNP) using a Hitachi SU‐6600 field
emission SEM (Hitachi, Maidenhead, UK) at an accelerating voltage
of 25 kV and working distance of 8 mm. Before SEM analysis, 5 μl of
each sample was drop‐cast on to a 5 × 5 mm pure silicon wafer sub-
strate (Ted Pella Inc., Redding, California, USA) 24 hours before
obtaining micrographs and allowed to air dry. Before scanning trans-
mission electron micrograph (STEM) analysis, 3 μl of each sample
was drop‐cast on to a carbon formvar copper grid (Agar Scientific
Ltd., Stanstead, UK) 24 hours before obtaining micrographs and
allowed to air dry.
2.7 | Cell culture and exposure
THP1 (ATCC®; TIB‐202™) a suspension line derived from a human
peripheral blood monocyte from an acute monocytic leukaemia
patient, was used for this study. THP1 cells were cultured in RPMI‐
1640 media containing 2 mM L‐glutamine (Sigma‐Aldrich) supple-
mented with 10% fetal bovine serum and incubated at 37°C, 95%
humidity and 5% CO2.
For particle exposure, cells were seeded in to a 96‐well plate at a
density of 1 × 104 cells in 100 μl of culture media for a 24 and 48 hour
time period. A minimum of three independent experiments were con-
ducted and for each independent experiment, six replicate wells were
employed per concentration per plate. The cells were then treated with
un‐encapsulated (AgNP) and Lipo‐AgNP after seeding. A positive kill
control, a 10% (v/v) dimethyl sulfoxide solution was prepared in
serum‐free media to treat the cells while a negative control of unex-
posed cells was also incorporated on to the plate for both AgNP‐ and
Lipo‐AgNP‐exposed cells. An additional positive control was performed
for THP1 cells exposed to 0.325–5 μg ml–1 Ag+ solution, prepared by
dissolving corresponding amount of AgNO3 in ddH2O, to test the pos-
sible influence of AgNP ionization into Ag+ on its cytotoxic effect.
2.8 | Cell viability
Cellular viability was evaluated with the Alamar Blue assay (AB). Briefly,
a 10% (v/v) AB solution in serum‐free media was prepared and kept
warm in a water bath at 37°C. The plate containing treated cells was
centrifuged in a Heraeus Megafuge 16R (Thermo Fisher) at 500 g and
20°C for 5 minutes and the exposure media removed after which
100 μl of the 10% AB solution was added to each well. The plates were
then incubated for 3 hours after which the resulting fluorescence of the
converted AB dye was measured at 540 and 595 nm excitation and
emission wavelengths respectively using SpectraMax® M3 Multi‐
Mode Microplate Reader and compared to the relative controls.
2.9 | Reactive oxygen species assay
ROS generation in the THP1 cells because of particle exposure was
measured with a carboxy‐DCFDA assay. In the assay carboxy‐DCFDA
a non‐fluorescent dye is metabolized by esterase into H2DCFDA,
which is further oxidized by ROS generated in the cell to a green fluo-
rescent DCFDA dye. To quantify ROS generation, theTHP1 cells were
seeded into a T75 flask at 5 × 105 cells ml–1 in RPMI media containing
2% fetal bovine serum and the cells were loaded with 10 μM of
carboxy‐DCFDA dye and incubated for 30 minutes under normal cul-
ture condition. The loaded cells were then centrifuged at 300 g for
5 min and the medium containing excess carboxy‐DCFDA was
removed. The loaded cells were then washed twice in warm sterile
phosphate‐buffered saline (PBS) and then re‐suspended in normal cul-
ture media. The cells were then seeded into Corning 96‐well solid
black plates (VWR, Dublin, Ireland) at 2 × 105 cells ml–1 and treated
with AgNP or Lipo‐AgNP at 0.3 μg ml–1. ROS generation was then
quantified by the fluorescence of the oxidized carboxy‐DCFDA, by
monitoring the dye emissions at 535 by 485 nm excitation on a
Spectramax M3 multiplate reader, using multi‐well scan at five differ-
ent points per well.
2.10 | Flow cytometry
For flow cytometry analysis THP1 cells were seeded and cultured in
T25 flasks at 2 × 105 cells ml–1 and were subsequently treated with
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Lipo‐AgNP and AgNP for 24 hours. After exposure, cells were har-
vested into 15 ml tubes and were centrifuged at 300 g for 5 minutes
at 22°C to form pellets. The pellets were resuspended in 2 ml
prewarmed 1× PBS and centrifuged as above and the process was
repeated. Before staining the pellet was finally resuspended in 1 ml
binding buffer a 0.1% NaN3 and 1% bovine serum albumin solution
in 1× PBS.
For live–dead staining the cells were double stained by adding 5 μl
of 1 μM calcein‐AM stain and 10 μl of 10 μg ml–1 PI. The cells were
then incubated in the dark at room temperature for 20 minutes and
analysed with a BD Accuri C6 flow cytometer (BD, Oxford, UK).
For the cell cycle analysis, cells were harvested as above and
rinsed in warm sterile PBS. The cells were then fixed with ice‐cold
70% ethanol. After ethanol fixation, the cells were incubated at 4°C
for up to 4 hours. Before any staining, the cells were washed twice
in PBS and centrifuged at 800 g for 5 minutes and the cell pellet
treated with 50 μl of a 100 μg ml–1 ribonuclease A to ensure only
DNA was stained. The cells were then stained with 400 μl of 50 μg
ml–1 PI and incubated for 10 minutes before analysing using BD Accuri
C6 flow cytometer.
Finally for Caspase3/7 analysis, as before the THP1 cells treated
with AgNP and Lipo‐AgNP were harvested and centrifuged at 300 g
for 5 minutes to remove exposure solutions. As a positive control,
THP1 cells were exposed to 1 μM solution of doxorubicin, which is a
known activator of the executioner caspases. The cells were washed
in PBS once and then resuspended in binding buffer. The cells were
then stained with 500 nM CellEvent caspase 3/7 detection reagent
and incubated at 37C for 30 minutes. The cells were then stained with
1 μM SYTOX AAdvanced dead cell stain and incubated for 5 minutes
before being analysed on a BD Accuri C6 flow cytometer.
2.11 | Statistical analysis
Statistical analysis was carried out using GraphPad Prism version 7.
Data were analysed by two‐way analysis of variance followed by
Tukey's multiple comparison tests to detect significance in effects
between exposure groups. Statistically significant differences in tests
were indicated for P < 0.05.
3 | RESULTS
3.1 | Particle characterization
A summary of the synthesized NPs characterization using DLS is
shown in Table 1 for different dispersion environments. DLS analysis
of AgNP showed a dramatic increase in mean particle size when dis-
persed in RPMI‐1640 media when compared to dispersion in ddH2O
from 21.24 to 79.15 nm respectively. This increase in size was accom-
panied by a change in colour of the AgNP when dispersed in RPMI‐
1640 from the usual golden yellow colour to dark grey. In contrast,
there was no significant change in the mean particle size of Lipo‐AgNP
when dispersed in RPMI‐1640 compared to ddH2O and no colour
change when dispersed in RPMI‐1640 media. There was an observable
increase in polydispersity index (PDI) of the AgNP (PDI = 0.23–0.566)
and the Lipo‐AgNP (PDI = 0.105–0.421) when dispersed in water
compared to dispersion in RPMI‐1640 media. However, no sedimenta-
tion was observed for the AgNP when dispersed in RPMI‐1640 likely
due to the concentration used. There was a measurable drop in zeta
potential values for AgNP (zeta = –26.5 to –7.9 mV) and Lipo‐AgNP
(zeta = –31.9 to –0.61 mV) when dispersed in ddH2O to RPMI‐1640
media, indicating a less stable NP in RPMI‐1640 media.
As shown in Figure 1(B), energy dispersive X‐ray analysis con-
firmed the presence of elemental AgNP in the sample as the strong
peak at 3 keV. The other peaks observed correspond to other elements
due to sample preparation, the substrate (Si wafer) and carbon tab for
conductive support. Result from XRD characterization of AgNP is
shown in Figure S1(C). The XRD pattern shows four main peaks for
AgNP at 2θ values of 38.30°, 44.55°, 64.60° and 77.55°, which corre-
sponds to (111), (200), (220) and (311) planes respectively for the face‐
centred cubic structure of metallic silver. This pattern is in agreement
with that of the Joint Committee on Powder Diffraction Standards file
no. 04‐0783 confirming the crystalline structure of the synthesized
AgNP (Luna, Barriga‐Castro, Gómez‐Treviño, Núñez, & Mendoza‐
Reséndez, 2016). The average size of synthesized AgNP was estimated




Where D is the size of AgNP crystal in nm, λ is the wavelength of
the diffractometer, β is the full width at half maximum intensity and θ
is the Bragg angle. Based on the equation, the size of AgNP crystal was
estimated to be 18.7 nm, which was similar to that of the average size
as determined by DLS measurement of 21.24 nm.
SEM and STEM were used to evaluate the morphology of the NPs
and to estimate the size distribution values of the NPs in dry state. The
STEM analysis of AgNP showed all particles produced were spherical
with an average size of 14.3 ± 1.9 nm, which is similar to that estimated
by the XRD analysis (Figure S1A). SEM analysis of Lipo‐AgNP showed
spherical and uniformly extruded vesicles while the contrasting image
of the STEM showed encapsulation of the AgNP in the liposome with
an average size of 82.73 ± 29.23 nm (Figure 2A,B), which displays size
values less than the DLS values, which considering the hydrodynamic
radius of the NPs was expected (Table 1). To confirm the encapsula-
tion, DLS values of both AgNP before and after encapsulation were
overlaid to determine if any unencapsulated AgNPs were present in
the test sample (Figure 2C). As expected, there was no overlap in the
size values showing successful encapsulation of AgNP.
TABLE 1 Size and zeta potential of AgNP, lyophilized and extruded
Lipo‐AgNP in ddH2O and RPMI‐1640 media
In ddH2O In media
Intensity PSD Intensity PSD
AgNP DLS (nm) 21.14 ± 9.48 79.15 ± 66.67




DLS (nm) 140.1 ± 47.49 138.9 ± 54.93
Zeta (mV) –31.9 –0.61
PDI 0.105 0.421
AgNP, silver nanoparticle; ddH2O, distilled deionized water; DLS, dynamic
light scattering; Lipo‐AgNP, liposomal silver nanoparticle; PDI, polydisper-
sity index; PSD, particle size distribution.
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3.2 | Encapsulation efficiency
Encapsulation efficiency of Lipo‐AgNP was estimated based on Equa-
tion 2. A 10 μg ml–1 AgNP solution (representing total AgNP added)
was used to rehydrate the lipid film and the liposome was prepared
as described above. The encapsulation efficiency of the different
Lipo‐AgNP preparations (Lipo‐AgNP L1–L3) are shown in Table 2
was between 85% and 89% of the total AgNP added before
encapsulation.
3.3 | Cellular viability study
The cell viability of THP1 cell line was evaluated by AB assay. The
assay evaluates the ability of metabolically active cells to reduce
FIGURE 1 Silver nanoparticles characterisation by scanning transmission electron micrograph, energy dispersive X‐ray and X‐ray diffraction.
Characterization of nanoparticles showing (a) scanning transmission electron micrograph, (b) energy dispersive X‐ray analysis of silver
nanoparticles on a silicon wafer and (C) X‐ray diffraction pattern of silver nanoparticles synthesized by chemical reduction method
FIGURE 2 Lipo‐AgNP characterization by scanning electron micrograph/scanning transmission electron micrograph and dynamic light scattering.
Characterization of nanoparticles showing (a) scanning transmission electron micrograph, (b) scanning electron micrograph and (c) superposition of
AgNP dynamic light scattering analysis before and after encapsulation in extruded liposome. AgNP, silver nanoparticle; Lipo‐AgNP, liposomal silver
nanoparticle
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resazurin, a non‐fluorescent blue dye to resorufin, a pink fluorescent
product. Reduction of resazurin is done by both mitochondrial and
cytoplasmic reducing agents such as NADPH, NADH, FMNH and
FADH, and as such the assay gives a broad indication of cellular viabil-
ity (Rampersad, 2012). THP1 cells were exposed to varying concentra-
tions of AgNP and Lipo‐AgNP (0.3–5 μg ml–1) for 24 and 48 hours. To
evaluate possible ionization of AgNP into Ag+, we exposed THP1 cells
to same concentration of Ag+ for 24 hours. At 24 hours, there was sig-
nificant reduction in THP1 cell viability treated with 2.5 μg ml–1 of
Lipo‐AgNP and cells treated with 5 μg ml–1 AgNP and Lipo‐AgNP
when compared with the unexposed control cells (Figure 3A). Interest-
ingly, the cytotoxic effect of Ag+ was threefold that of AgNP, showing
a highly significant reduction in THP1 cell viability at concentrations
0.625–2.5 μg ml–1 and twofold reduction at 5 μg ml–1 after 24 hours.
Ag+ induced significant reduction inTHP1 cell viability when compared
with AgNP at concentrations ≥0.625 μg ml–1. The IC50 of AgNP, Lipo‐
AgNP and Ag+ at 24 hours was estimated to be 4.991, 3.045 and
0.3226 μg ml–1 respectively. At 48 hours, there was a significant
reduction in cell viability for all exposure groups and concentration
when compared to control. Interestingly, it induced a significant reduc-
tion inTHP1 cell viability by 2.5 μg ml–1 of Lipo‐AgNP compared to the
AgNP at the same concentration (Figure 3B). Cell viability for Ag+ was
not carried out at 48 hours as ≤20% cell viability was already observed
at 24 hours. To ensure the cytotoxic effect of Lipo‐AgNP was due to
the encapsulated AgNP and not the liposome, we exposed THP1 cells
to empty liposome at the same concentrations with 1.25 and 2.5 μg
ml–1. THP1 cell viability after 24 hours' exposure showed no significant
difference when compared with unexposed THP1 cells (Supporting
information, Figure S1).
To verify the AB findings, the levels of THP1 cell viability after
exposure were monitored by flow cytometry. Flow cytometry is a sin-
gle cell analysis method and because it gives a better indication of the
exact viability levels in the exposures when compared to the AB assay.
THP1 cell death was evaluated by initially staining the cells with
calcein‐AM and PI 24 hours after being exposed to 0.625 μg ml–1 of
AgNP and Lipo‐AgNP. Compared to an unexposed control as with
the previous viability measurements, 10% dimethyl sulfoxide medium
solution was used as a positive control.
From the results obtained, there was no significant difference in
the percentage of live cells between the control (98.35%) and AgNP‐
treated cells (98.55%) after 24 hours. However, we discovered a highly
significant difference in the percentage of live cells treated with
Lipo‐AgNP (66.75%) compared with AgNP (Figure 4). In both control‐
unexposed and AgNP‐treated cells, only 0.5% cell death was observed
after 24 hours. Contrarily, Lipo‐AgNP treatment induced cell death in
32.5% of THP1 cells, a highly significant increase in cell death com-
pared with both control‐unexposed and AgNP‐treated THP1 cells after
24 hours. This result suggests Lipo‐AgNP is capable of inducing cell
death at lower dose than that established by AB assay.











Encapsulation efficiency 88.7% 85.0% 85.7%
AgNP, silver nanoparticle; Lipo‐AgNP, liposomal silver nanoparticle.
FIGURE 3 Cell viability of (a) AgNP, Lipo‐AgNP and Ag+ exposed cells at 24 hours and (b) AgNP and Lipo‐AgNP at 48 hours as determined by the
Alamar blue assay. Data are expressed as a percentage of three independent experiments ± standard error of the mean of the four individual
experiments and relative to a two‐dimensional culture control. Statistically significant differences between the exposed viability responses and that
of the control cultures are denoted by *P < 0.05, **P < 0.01, ****P < 0.0001. AgNP, silver nanoparticle; Lipo‐AgNP, liposomal silver nanoparticle
FIGURE 4 Lipo‐AgNP induced THP1 cell death. Control THP1 cells,
and cells treated with 0.625 μg ml–1 of AgNP and Lipo‐AgNP and
10% DMSO were incubated for 24 hours and were washed in
phosphate‐buffered saline before staining with 10 μg ml–1 propidium
iodide and 10 nM calcein‐AM. Data represent mean percentage ±
standard error of the mean (n = 3). ****P < 0.0001. AgNP, silver
nanoparticle; DMSO, dimethyl sulfoxide; Lipo‐AgNP, liposomal silver
nanoparticle
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3.4 | Cell cycle analysis
THP1 cells were exposed to 0.625 μg ml–1 of AgNP and Lipo‐
AgNP while unexposed cells were used as controls. Cell cycle anal-
ysis after 24 hours of exposure showed that exposure of THP1
cells to both AgNP and Lipo‐AgNP did not affect the cell cycle pro-
gression from G1 to S phase and there was no significant difference
between the exposed cells to control‐unexposed cells. Exposure of
THP1 cells to Lipo‐AgNP resulted in 21.1% cells in the G2/M phase
of the cell cycle. As expected, AgNP treatment did not show any
effect on cells in the G2/M phase having 32.65% cells comparable
to the 30.85% unexposed‐control cells in G2/M phase. Interestingly,
it was found that Lipo‐AgNP treatment resulted in 8.4% cells in the
sub‐G1 phase compared with 0.65% and 0.8% cells for both unex-
posed‐control and AgNP‐treated cells respectively (Figure 5). This
indicated that Lipo‐AgNP at low doses caused DNA fragmentation,
which was evident by the characteristic of sub‐G1 peak. The per-
centage of cells in the G0/G1 and S phases remained the same in
all groups, suggesting no apparent effect of treatment on cells in
all exposure groups
3.5 | Reactive oxygen species induction
DNA fragmentation is one of the consequences of ROS generation
before apoptosis. To determine if low‐dose Lipo‐AgNP was inducing
the generation of ROS at sufficient levels to induce DNA damage,
ROS levels were monitored in THP1 cells exposed to 0.3 μg ml–1
Lipo‐AgNP at varying time points indicated in Figure 6 alongside an
unexposed‐control and uncapped AgNP to plot ROS generation as a
function of time. From 30 minutes to 5 hours, there was an average
of 1.5‐fold induction of ROS in cells exposed to 0.3 μg ml–1 of AgNP
compared to control cell ROS. Cells exposed to the same concentra-
tion of Lipo‐AgNP showed mild suppression of ROS induction up to
4 hours, which significantly increased to approximately threefold of
control ROS at 24 hours. This indicates that ROS generation was not
responsible for the observed cell death in THP1 cells exposed to
0.3 μg ml–1 of Lipo‐AgNP.
3.6 | Caspase activation
ROS and DNA damage are known to be indicators of apoptosis and to
verify this was the mechanism of action utilized by Lipo‐AgNP, the
CellEvent Caspase‐3/7 Green Detection Reagent and SYTOX
AADvanced Dead Cell Stain were employed. THP1 cells exposed to
0.625 μg ml–1 of AgNP and Lipo‐AgNP were stained after 1, 4 and
24 hours of exposure. The result showed basal caspase activities at 1
and 4 hours in all exposure groups with an average of 2% of the total
cell population exhibiting caspase activities. After 24 hours of expo-
sure, the level of caspase activation remained the same for control‐
unexposed cells and AgNP‐treated cells. Conversely, 33% of total
THP1 cells exposed to Lipo‐AgNP were positive for caspase activation
at 24 hours (Figure 7). This result suggested the cell death observed in
Lipo‐AgNP exposed cells was likely a consequence of caspase‐3/7
activation.
FIGURE 5 Lipo‐AgNP treatment induced DNA fragmentation: THP1
cell lines were treated with 0.625 μg ml–1 of Lipo‐AgNP and AgNP
while unexposed cells and 10% dimethyl sulfoxide‐treated cells were
used as controls. Data represent mean percentage ± SEM (n = 3), *P <
0.05. AgNP, silver nanoparticle; Lipo‐AgNP, liposomal silver
nanoparticle
FIGURE 6 THP1 cell lines were loaded with 10 μM 6‐carboxy‐2′,7′‐
dichlorofluorescein diacetate dye for 20 minutes. After which they
were exposed to 0.3 μg ml–1 AgNP and Lipo‐AgNP for up to 4 hours.
Control value was set as baseline for all time points and represented as
mean ± standard error of the mean (n = 3). AgNP, silver nanoparticle;
Lipo‐AgNP, liposomal silver nanoparticle; ROS, reactive oxygen
species
FIGURE 7 Lipo‐AgNP activates caspase‐dependent apoptosis in
THP1 cells after 24 hours. THP1 cells that were unexposed, treated
with 0.625 μg ml–1 of AgNP, 0.625 μg ml–1 of Lipo‐AgNP and 1 μM
doxorubixin were stained with 500 nM CellEvent™ for 30 minutes and
co‐stained with 1 μM Sytox AADvanced during the last 5 minutes.
Data are represented as mean ± standard error of the mean (n = 3),
****P < 0.0001. AgNP, silver nanoparticle; Dox, doxorubixin; Lipo‐
AgNP, liposomal silver nanoparticle
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4 | DISCUSSION
Currently AgNPs are the main active ingredient in multiple nano‐
enabled commercial products worldwide, primarily due to their antimi-
crobial activities. Despite this, several studies have investigated and
identified the cytotoxicity related hazards associated with AgNP
(Connolly et al., 2015; Nowrouzi et al., 2010; Zhang, Wang, Chen, &
Chen, 2014). Interestingly, the increasing investigation of AgNP cyto-
toxicity has now moved beyond antibacterial applications and recent
studies are investigating the potential of AgNPs as anticancer drugs.
This shift is partially due to the evolution of multidrug‐resistant cancer
cells similar to that of antibiotic‐resistant bacteria. Foldbjerg et al.
(2012) noted that AgNP at an EC20 of 12.1 μg ml
–1 showed potential
anticancer properties such as induction of ROS, modulation of cell divi-
sion and growth regulatory gene expressions such as cyclin B1 and his-
tone H1B and the arrest of cells in the G2/M phase. Lin et al. (2014)
showed that 10 μg ml–1 of AgNPs produced enhanced cytotoxicity in
HeLa and B16 mouse melanoma cell lines that have undergone chemo-
therapeutic or genetically induced autophagy inhibition by preventing
formation of anti‐apoptotic autophagosomes normally induced by
AgNP in these cell lines. Asharani et al. (2012) showed that 400 μg
ml–1 of AgNP induces activation of γH2AX foci, suppresses expression
of key cell cycle proteins such as p21, p53 and cyclin B, and induces
the expression of DNA damage response genes RPA1 and FEN1. Sev-
eral other studies evaluating the antibacterial properties and mecha-
nism of action of AgNP have shown the minimum inhibitory
concentration of AgNP from 10 μg ml–1 to as high as 180 μg ml–1
for different bacteria strains (Amato et al., 2011; Bao et al., 2015;
Guzman, Dille, & Godet, 2012; Hsueh et al., 2015; Maiti, Krishnan, Bar-
man, Ghosh, & Laha, 2014). None the less, all of these studies have
investigated AgNP activities at high concentrations, which are likely
to be detrimental to human health, thus limiting the potential thera-
peutic applications. Hence, this necessitates development of delivery
systems capable of delivering AgNPs intracellularly at a lower concen-
tration to achieve the desired pharmacological response.
In this study, an in‐house synthesized AgNP was encapsulated to
improve the in vitro delivery of the AgNP to enhance their in vitro
effects and simultaneously reduce the dose required. NPs are found
in bodily tissues and fluid after entering the body through different
routes such as oral, intravenous, transdermal or inhalation (Yildirimer,
Thanh, Loizidou, & Seifalian, 2011). The use of THP1 in the study
was to mimic such presence in the blood system because of relocation
in a diseased condition and as an enhanced delivery mechanism for
cancer. There are multiple reports on the effect of NP size on drug
delivery and cellular internalization. NPs of larger sizes (<500 nm)
are, in addition to hepatic uptake, more prone to clearance by the retic-
uloendothelial system resulting in reduced bioavailability and pharma-
cological potential (Alexis, Pridgen, Molnar, & Farokhzad, 2008; Omar
Zaki, Ibrahim, & Katas, 2015). Both the DLS and SEM/STEM character-
ization showed the sizes of the AgNP and Lipo‐AgNP to be below 30
and 200 nm respectively. In general, DLS values were slightly higher
than that of the SEM values and this was as expected as the DLS is
an intensity measurement that tracks the hydrodynamic radius of the
solvated NP while SEM/STEM imaging is a physical snapshot of the
dry particles with no influence from surrounding solvent. As such,
the hydrodynamic radius, which includes the aqueous layer, tends to
be slightly larger than dry particle radius. The XRD pattern analysis
using the Debye–Scherrer equation estimated a size of 18.7 nm and
peak pattern that is characteristic of a face‐centred cubic crystalline
structure. This finding is in agreement to those of other studies further
confirming the sample as metallic silver (Anandalakshmi, Venugobal, &
Ramasamy, 2016; Bindhu & Umadevi, 2015). However, there are two
peaks around 26° and 30.7°, which are not characteristic of silver.
These peaks may be generated by the NaBH4 reducing agent used in
chemical reduction of AgNO3 and it is similar to those reported in
other studies for NaBH4 (Agnihotri, Mukherji, & Mukherji, 2014; Su,
Lu, Wang, & Huang, 2012).
Several studies have noted particle size changes of AgNP in cell
culture environments, as such the size distributions of AgNP and
Lipo‐AgNP in culture media were monitored and compared to those
in water. An AgNP size increase from 21.14 to 79.15 nm was observed
in media compared to when dispersed in water. This size increase was
presumed to be an indication of NP agglomeration in the solution. In
contrast, this was not the same for Lipo‐AgNP where there was a slight
reduction in recorded sizes (140.1 nm in water and 138.9 nm in media).
Previous studies have reported an increase in AgNP size in culture
media and this increase in size has been proposed to be due to an asso-
ciation of AgNP with proteins (Hansen & Thunemann, 2015;
Mukherjee, O'Claonadh, Casey, & Chambers, 2012; Murphy, Sheehy,
Casey, & Chambers, 2015; Shannahan et al., 2013). The interaction
of AgNP with protein in culture media was most likely prevented by
Lipo‐AgNP due to the presence of the protective lipid layer, preventing
the encapsulated AgNP from directly interacting with biomolecules in
the milieu of the culture media. Additionally, there was an increase
in PDI values for AgNP in both water and RPMI‐1640, the difference
in these PDI values for AgNP was higher than that of Lipo‐AgNP.
PDI value increases indicate an increased non‐uniformity of the NPs
when they were dispersed into the culture media. These findings sug-
gest encapsulation and formation of the Lipo‐AgNP suppresses the
changes in morphology of AgNP in culture media and ultimately
improves their stability in comparison to standard AgNP.
After dispersion, cellular viability levels of THP1 cells exposed to
varying concentration of AgNP and Lipo‐AgNP (0.3–5 μg ml–1) for 24
and 48 hours were monitored with the AB assay. The results showed
a dose‐dependent reduction in cell viability with a greater level of
cytotoxicity observed for the Lipo‐AgNP‐treated cells. A significant
THP1 cell viability reduction was observed at 2.5 μg ml–1 Lipo‐AgNP
treatment (P < 0.05) and interestingly not for AgNP of the same con-
centration after 24 hours. In contrast, there was a significant reduction
in cell viability of THP1 cells treated with 2.5 μg ml–1 Lipo‐AgNP com-
pared to AgNP of the same concentration at 48 hours (P < 0.0001),
suggesting Lipo‐AgNP were more cytotoxic than AgNP. AgNP only
induced significant reduction in cell viability at 5 μg ml–1 and ≥2.5 μg
ml–1 at 24 and 48 hours respectively when compared to control. This
finding is in agreement with those of other studies that investigated
dose‐dependent cytotoxicity of AgNP on different human cell lines.
Jiang et al. (2013) reported significant reduction of Chinese hamster
ovary k1 cell viability at concentrations ≥5 μg ml–1 at 24 hours using
MTT assay. Juarez‐Moreno et al. (2016) in their study reported similar
AgNP IC50 to that of this study in addition to significant reduction in
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cell viability at AgNP concentrations ≥1.25 μg ml–1 for eight different
human cancer cell lines where viability was monitored with the MTT
assay. Variations in the cytotoxicity of AgNP in these cell lines could
be attributed to the difference in sensitivity of the cell lines to the
NP but also differences in assays employed to monitor viability. Inter-
estingly, Murphy, Casey, Byrne, Chambers, and Howe (2016) who used
THP1 cells reported dose‐dependent cytotoxicity of AgNP (50–70 nm
size) with significant difference from ≥1.9 μg ml–1. This contrasted
with our findings and could be due to polyvinyl pyrrolidine‐coated
AgNP used in the study, which may have its own inherent toxicity.
Of course, it may be because of a difference in particle sizes, which
have been previously shown to mediate cytotoxicity irrespective
of capping agent used (Gliga, Skoglund, Wallinder, Fadeel, &
Karlsson, 2014).
AgNP ionization into Ag+ has been widely proposed as its mecha-
nism of action in inducing cytotoxicity (Hsueh et al., 2015; Lansdown,
2010). As such, we investigated the cytotoxicity of Ag+ on THP1 cells
and our findings indicate that Ag+ at concentrations between 0.625
and 2.5 μg ml–1 reduced THP1 cell viability by more than threefold
while twofold reduction in cell viability was observed for THP1
exposed to 5 μg ml–1 Ag+ when compared with AgNP at the same con-
centrations. This finding is in agreement with that of Foldbjerg et al.
(2009) who used flow cytometric analysis to determine viability of
THP1 cells after exposure to AgNP and Ag+. Their findings showed
at least a twofold reduction in THP1 cell viability after exposure to
≥0.625 μg ml–1 Ag+. There was a similar concentration‐dependent
cytotoxicity profile for both AgNP and Ag+ although Ag+ had higher
toxicity. Taken together, ionization of AgNP into Ag+ is likely responsi-
ble for the cytotoxic effect of AgNP. The lower cytotoxic effect of
AgNP may be because of its slow ionization rate as it has been
reported that the AgNP ionization rate correlates with its concentra-
tion (Maurer‐Jones, Mousavi, Chen, Buhlmann, & Haynes, 2013). This
is also supported by the reduction in Ag+ cytotoxic effect to twofold
relative to that of AgNP at 5 μg ml–1. This may be consequent upon
increased ionization of AgNP with increased concentration. In addition,
the steady reduction in THP1 cell viability after 48 hours of exposure
to 0.625–2.5 μg ml–1 of AgNP also supports this notion.
To verify the results of the AB assay, flow cytometry, which is a
more sensitive technique, was employed to evaluate cell viability after
exposure to THP1 cells with AgNP and Lipo‐AgNP. Calcein‐AM and PI
staining of THP1 cells after 24 hours of treatment with 0.625 μg ml–1
Lipo‐AgNP showed induction of a significant amount of death in the
cells (P < 0.0001). Conversely, AgNP treatment showed a comparable
outcome to control‐unexposed cells with little or no cell death
observed, verifying the AB assay results that the Lipo‐AgNP exhibited
a higher level of cytotoxicity than AgNP alone.
Several studies have shown that AgNP can initiate cell cycle arrest
at different phases of the cell cycle including the G0/G1, S and G2/M
phases (Asharani et al., 2012; De Matteis et al., 2015; Eom & Choi,
2010). As such, the effect of low‐dose Lipo‐AgNP on the THP1 cell
cycle was monitored. Our findings showed normal progression of
THP1 cells from the G1 to the S‐phase for all exposure and control
groups. On the contrary, Lipo‐AgNP exposure resulted in a significant
reduction in G2/M cell population compared with the control and
AgNP‐treated cells (P < 0.05). In the S‐phase, cells that have
successfully passed through the G1/S checkpoint replicate their DNA
in preparation for progression into the G2/M phase where they divide
during mitosis (Takeda & Dutta, 2005). DNA damage in the S
phase results in activation of ataxia–telangiectasia‐mutated and
ataxia–telangiectasia‐related kinases, which in turn activate CHK2,
γH2AX and the BRCA genes to slow down replication through abroga-
tion of origin firing and signal DNA damage for repair. Increased DNA
damage, however, results in induction of apoptosis by ataxia–telangi-
ectasia‐mutated, ataxia–telangiectasia‐related and CHK2 activation
of p53 (Norbury & Zhivotovsky, 2004; Willis & Rhind, 2009). A popu-
lation in the sub‐G1 upon Lipo‐AgNP exposure was noted and such
populations are known to be cells with fragmented DNA that are
undergoing or have undergone apoptosis. A genomic DNA
fragmenting effect of AgNP has indeed been previously demonstrated
by Awasthi et al. (2013) and may be occurring in this study after expo-
sure to Lipo‐AgNP. The proportion of cells observed in the sub‐G1
recorded because of Lipo‐AgNP exposure matches the reduction in
the G2/M phase. This may indicate the cells were forced out of the cell
cycle due to the increased DNA damage because of Lipo‐AgNP expo-
sure and died via apoptotic mechanisms.
The cell induces apoptosis for many reasons, one of which is to
maintain genome integrity by killing cells with a high amount of DNA
damage. ROS induction is often used to activate the signalling cascade
that results in apoptotic induction in such cells. ROS are known to dis-
rupt the mitochondrial membrane that results in the release of cyto-
chrome c. Release of cytochrome c activates the proapoptotic Bcl2
proteins Bax and Bak, which in turn activate executioner caspases 3
and 7 (Quast, Berger, & Eberle, 2013). There are reports in the litera-
ture indicating that AgNPs cause apoptosis by inducing increased gen-
eration of ROS. Indeed Kang et al. (2012) and Foldbjerg, Dang, and
Autrup (2011) reported a dose‐ and time‐dependent ROS‐induced
apoptosis in dendritic cell line (DC2.4) and A549 lung cell lines respec-
tively because of AgNP exposure. Awasthi et al. (2013) also reported a
dose‐dependent ROS generation and induction of apoptosis in Chi-
nese hamster ovary cell lines. To monitor if this was occurring here
because of the Lipo‐AgNP exposure, ROS generation was monitored
in THP1 cell lines. The cells were treated with a low concentration of
AgNP and Lipo‐AgNP (0.3 μg ml–1) for up to 4 hours to evaluate the
onset of ROS generation. It was noted that AgNP exposure did induce
ROS, but non‐significant levels of ROS with respect to the controls,
most likely because the concentrations considered were not cytotoxic
to the cells. In contrast to the previous studies, this study showed that
Lipo‐AgNP did not induce ROS generation to causeTHP1 cell death. In
fact, there was an observable suppression of ROS induction. The vari-
ation in these studies can likely be due to several factors, which include
but are not limited to differences in cell lines, size and surface charac-
teristics of the AgNP used.
The literature indicates cell death because of AgNP exposure is
typically due to ROS generation with subsequent DNA damage to
the cells followed by apoptosis. However, findings of this study sug-
gested ROS was not involved in the induction of observed cell death
when studying the Lipo‐AgNP. One of the downstream factors acti-
vated by p53 signalling after sensing DNA damage is caspase 3. Differ-
ent studies have shown that activation of p53 in response to DNA
damage results in p53 transcriptional upregulation of Puma and Noxa,
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inhibitors of Bcl‐2, Bcl‐xl and Mcl‐1. Inhibition of these Bcl proteins
result in Bax and Bak activation, which ultimately result in cytochrome
c release and activation of the executioner caspases (Ashkenazi, 2008).
To explore the possibility of ROS‐independent induction of apoptosis,
activation of caspases 3/7 in THP1 cells treated with the same low‐
dose AgNP and Lipo‐AgNP at 1, 4 and 24 hours to monitor onset of
activation was investigated. For all cell groups, there was no significant
activation of caspases 3/7 at 1 and 4 hours. On the other hand, there
was a significant induction of caspases 3/7 in THP1 cells treated with
0.625 μg ml–1 of Lipo‐AgNP after 24 hours (P < 0.0001).
Previous studies have linked the AgNP mechanism of action to
increased generation of ROS, which causes depolarization of the mito-
chondrial membrane potential and subsequent rupture of the mem-
brane for release of cytochrome c (Foldbjerg et al., 2011; Jiang et al.,
2013; Kang et al., 2012). This has been proposed to be achieved by
the intracellular oxidation of AgNP to Ag+ by the acidic environment
in the lysosome (De Matteis et al., 2015). Endocytosis of AgNP is
believed to result in the compartmentalization of the NP in an endo-
some, which is metabolized in the endolysosomal pathway thus leading
to its oxidation and generation of ROS. Our findings have interestingly
opened an alternative pathway to ROS‐dependent apoptosis induction
by AgNP. In this study, it was shown that encapsulation of AgNP in
liposomes was able to achieve greater cytotoxicity at low dose com-
pared to what was achievable at high doses, in a ROS‐independent
way. This may be attributed to the improved delivery of AgNP into
the cells via the liposome as the lipid layer can easily traverse the lipid
bilayer of the cell membrane due to the hydrophobic interactions when
compared to unencapsulated AgNP. Lipo‐AgNP may also suppress the
ionization of AgNP as part of its mechanism to prevent ionization‐
dependent generation of ROS. Conventional drugs encapsulated in
liposome are known to have an increased bioavailability, enhanced
permeability and retention effect (Maeda, 2012). These characteristics
enhance the pharmacokinetics of Lipo‐AgNP in the cells resulting in
efficient delivery of AgNPs into the cell. Lysosomal breakdown of the
lipid layer will result in overwhelming delivery of AgNP into the cyto-
plasm and subsequently in the nucleus allowing interaction between
AgNP and the DNA causing DNA damage and halted replication
(Li, Zhao, Hammer, Du, & Chen, 2013; Pramanik, Chatterjee, Saha,
Devi, & Suresh Kumar, 2016). The DNA damage could be responsible
for the activation of executioner caspases consequent upon activation
of p53. Taken together, this suggests a ‘Trojan Horse’ effect mecha-
nism for Lipo‐AgNP due to the sudden leakage of AgNP into the cyto-
plasm and subsequently the nucleus after degradation of the liposome.
This stealth mechanism none the less, is in contrast with the type pre-
viously described for AgNP in other studies where AgNP is phagocy-
tosed, ionized and released to enhance the generation of ROS, which
in turn stimulates inflammatory responses that can mediate cell death
(Park, Yi, Kim, Choi, & Park, 2010).
The cytotoxicity induced by Lipo‐AgNP independent of ROS gen-
eration offers some advantages if properly harnessed. ROS is known to
induce cellular senescence in neighbouring cells and this is accompa-
nied by upregulation of stress and inflammatory genes through secre-
tion of proinflammatory molecules such as nuclear factor kappa B
(Correia‐Melo, Hewitt, & Passos, 2014). In addition, ROS‐mediated
necrosis of cells could result in the release of cytoplasmic wastes that
can cause exaggerated and unscheduled inflammatory responses,
which may promote tumour development (Vakkila & Lotze, 2004). As
such, these secondary effects can be prevented by coating the AgNP
surface in a protective layer as demonstrated in this study.
5 | CONCLUSION
In this work, the encapsulation of AgNP in a liposome has been dem-
onstrated to enhance AgNP cytotoxicity at low concentrations through
increased DNA damage with suppression of ROS. This contrast with
several other studies that have shown that AgNP cytotoxic effect
can only be achieved through the generation of ROS. It is postulated
that the encapsulation of AgNP in liposomes could eliminate the neg-
ative side effects of ROS making it possible to achieve a greater level
of cytotoxicity that would otherwise only be possible at high concen-
trations. As such, Lipo‐AgNP could reduce the concentration of AgNP
required thereby increasing any potential biological activity with
reduced associated side effects typically caused from high‐dose
exposures.
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